ClinicalTrials.gg
RecruitingNCT07227207Updated Nov 2, 2026

A Study of TSRA-196 in Adults With PiZZ Alpha-1 Antitrypsin Deficiency (AATD)

A Phase 1/2 interventional study of TSRA-196 in Alpha-1 Antitrypsin Deficiency (AATD), sponsored by Tessera Therapeutics, Inc.. Recruiting at 9 sites in 4 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Tessera Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.
Updated Nov 2, 2026First site in Sweden1 site addedGo to Updates ↓
Phase
Phase 1/2
Study type
Interventional
Enrollment
72
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This is a Phase 1/2, open-label, multi-center, dose escalation (Part 1), dose expansion (Part 2), and single repeat dose (Part 3) study to evaluate the safety, tolerability, efficacy, and PK/PD parameters of TSRA-196 in adults with the PiZZ genotype who have lung and/or liver disease associated with severe alpha-1 antitrypsin deficiency (AATD)

02

Conditions studied

  • Alpha-1 Antitrypsin Deficiency (AATD)
03

In context

alpha 1-Antitrypsin Deficiency

142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.

This study's planned enrollment of 72 is above the median of 32 across 86 interventional studies indexed under alpha 1-Antitrypsin Deficiency.

Browse alpha 1-Antitrypsin Deficiency studies →

Lead sponsor

This is the only study on the registry with Tessera Therapeutics, Inc. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females who are 18 to 70 years of age, inclusive, at the time of signing the
  • of 18 to 37 kg/m2, inclusive
  • Confirmed diagnosis of AATD and PiZZ genotype
  • At least one previous measure of blood total AAT level \<11 µmol/L
  • Nonsmoker for at least 6 months before screening and must remain nonsmoking for the entire study duration
  • Either AAT treatment-naïve or washed out of all or approved treatments that modify AAT levels for 5 half-lives or at least 4 weeks, whichever is longer, before TSRA-196 administration

Parts 1A and 2A (AATD lung disease with no or minimal liver fibrosis)

  • lung disease, defined as 1) evidence of emphysema or bronchiectasis by computed tomography or 2) DLCO \<70% of the predicted value or 3) ppFEV1 \<80%
  • ppFEV1 ≥35%
  • METAVIR fibrosis score F0 or F1 confirmed by liver at screening, or a liver stiffness measure by FibroScan ≤7 kPa at screening
  • FIB-4 index score ≤3.25 at screening
  • and/or AST \< at screening

Parts 1B and 2B (AATD liver disease with significant or severe liver fibrosis, with or without AATD lung disease)

  • METAVIR fibrosis score F2 or F3 confirmed by liver biopsy at screening. A liver biopsy conducted within 12 months before screening is acceptable as a substitute.
  • Liver stiffness measure by FibroScan >7 and ≤15 kPa at screening
  • ALT and/or AST \<2 x ULN at screening

Exclusion criteria

Exclusion Criteria:

  • Presence of genetic variation in SERPINA1 gene that may disrupt the function of TSRA-196, determined by screening genotyping
  • History of liver disease unrelated to AATD, or history of or clinical signs of cirrhosis
  • Significant lung disease not attributable to manifestations of AATD, as determined by the investigator
  • History of one or more hospitalizations due to severe exacerbation of underlying lung disease during the year before screening or received IV antibiotics for treatment of a pulmonary infection within 6 months before screening
  • Unstable AATD-related , as determined by the investigator, or severe bronchiectasis
  • Lung volume reduction surgery within 1 year before screening or plan to receive lung volume reduction surgery during the study period
  • Documented chronic need for positive airway pressure therapy beyond nocturnal use
  • Seropositive for (HIV) (HIV-1 or HIV-2)
  • Seropositive for (hepatitis B surface antigen [HBsAg] or hepatitis B core antibody [HBcAb] positive) with detectable HBV DNA
  • virus (HCV) RNA positive at screening (Parts 1A and 2A), or HCV RNA positive and/or HCV antibody positive at screening (Parts 1B and 2B)
  • Has received an organ transplant or is on a waiting list for an organ transplant
  • Prior treatment with gene therapy using viral vectors or intended to permanently change the patient's DNA
  • Any products within 30 days before dosing or plan to take an investigational product before the end of study
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    TSRA-196 Drug Product

    Drug: TSRA-196

Interventions

  • DrugTSRA-196

    TSRA-196 is an in-vivo genome editing product formulated in lipid nanoparticles (LNPs) for the treatment of patients with alpha-1 antitrypsin deficiency (AATD), via intravenous (IV) infusion

06

What researchers measure

Primary outcomes

  1. Part 1 (Dose Escalation): Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)

    Time frame: 1 Year

  2. Part 2 (Dose Expansion): Proportion of participants who have serum levels of total alpha-1 antitrypsin (AAT) greater than or equal to Lower Limit of Normal (LLN) after TSRA-196 treatment

    Time frame: 1 Year

  3. Part 2 (Dose Expansion): Change in functional AAT concentrations (determined using an elastase inhibition assay) from baseline to end of study

    Time frame: 1 Year

  4. Part 3 (Single Repeated Dose): Proportion of participants who have serum levels of total alpha-1 antitrypsin (AAT) greater than or equal to Lower Limit of Normal (LLN) after a second dose of TSRA-196

    Time frame: 1 Year

Secondary outcomes

  1. Part 1 (Dose Escalation): Proportion of participants who have serum levels of total AAT greater than or equal to LLN after TSRA-196 treatment

    Time frame: 1 Year

  2. Part 2 (Dose Expansion): Incidence of TEAEs and SAEs

    Time frame: 1 Year

  3. Part 1 (Dose Escalation) and Part 2 (Dose Expansion): Proportion of participants who have serum levels of total AAT greater than or equal to 11 μM after TSRA-196 treatment

    Time frame: 1 Year

  4. Part 1 (Dose Escalation) and Part 2 (Dose Expansion): Change in serum levels of total AAT from baseline over time

    Time frame: 1 Year

  5. Part 1 (Dose Escalation) and Part 2 (Dose Expansion): Incidence of Adverse Event of Special Interest (AESI) from day of dosing through end of study

    Time frame: 1 Year

  6. Part 1 (Dose Escalation) and Part 2 (Dose Expansion): Change over time in safety measures, including clinical laboratory parameters, vital signs, and ECG parameters

    Time frame: 1 Year

  7. Part 1 (Dose Escalation) and Part 2 (Dose Expansion): Pharmacokinetic (PK) parameter: Area under the blood concentration time curves (AUC) of TSRA-196

    Time frame: 1 Year

  8. Part 1 (Dose Escalation) and Part 2 (Dose Expansion): PK parameter: Maximum observed blood concentration (Cmax) of TSRA-196

    Time frame: 1 Year

  9. Part 1 (Dose Escalation) and Part 2 (Dose Expansion): PK parameter: Time to Cmax (tmax) of TSRA-196

    Time frame: 1 Year

  10. Part 1 (Dose Escalation) and Part 2 (Dose Expansion): PK parameter: Half-life (t1/2) of TSRA-196

    Time frame: 1 Year

  11. Part 1 (Dose Escalation) and Part 2 (Dose Expansion): PK parameter: Clearance (CL) of TSRA-196

    Time frame: 1 Year

  12. Part 1 (Dose Escalation) and Part 2 (Dose Expansion): PK parameter: The volume of distribution at terminal stage (Vz) of TSRA-196

    Time frame: 1 Year

  13. Part 2 (Dose Expansion): Change in post-bronchodilator percent predicted forced expiratory volume (ppFEV1) from baseline through end of study

    Time frame: 1 Year

  14. Part 2 (Dose Expansion): Incidence of COPD exacerbations from baseline over time

    Time frame: 1 Year

07

Study locations

9 of 9 sites recruiting
  • Clinical Study Center
    Jacksonville, Florida 32224, United States
    Recruiting
  • Clinical Study Center
    Boston, Massachusetts 02118, United States
    Recruiting
  • Clinical Study Center
    Rochester, Minnesota 55905, United States
    Recruiting
  • Clinical Study Center
    Charleston, South Carolina 29425, United States
    Recruiting
  • Clinical Study Center
    Seattle, Washington 98195, United States
    Recruiting
  • Clinical Study Center
    Fitzroy, Victoria, Australia
    Recruiting
  • Clinical Study Center
    Gothenburg, Sweden
    Recruiting
  • Clinical Study Center
    London, United Kingdom
    Recruiting
  • Clinical Study Center
    Nottingham, United Kingdom
    Recruiting
08

Updates

1 registry update since Sep 25, 2026
Sites
1 site added — first site in Sweden
Show site
  • Clinical Study Center · Gothenburg, Sweden
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    1 site added — first site in Sweden
    Show site
    • Clinical Study Center · Gothenburg, Sweden
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07227207
Lead sponsor
Tessera Therapeutics, Inc.
Responsible party
Sponsor
First posted
Nov 12, 2025
Start date
Apr 21, 2026
Primary completion
Mar 2029 (estimated)
Completion
Mar 2029 (estimated)
Last update
Nov 2, 2026

Study contacts

Tessera Clinical Trials Information
Contact
clinicalinfo@tesseratx.com
857-271-4800

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion